Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
Want to see SNPHY full AI Analyst Report?
SNPHY Stock Chart & Stats
$11.00
-$0.45(-4.61%)
At close: 4:00 PM EST
$11.00
-$0.45(-4.61%)
Day’s Range― - ―
52-Week Range$9.66 - $12.20
Previous CloseN/A
Volume180.00
Average Volume (3M)1.01K
Market Cap
$3.85B
Enterprise Value$536.27B
Total Cash (Recent Filing)$81.23B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)14.6
Beta-0.03
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)116.58
Shares Outstanding322,290,160
10 Day Avg. Volume2,904
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio0.87
Price to Book (P/B)1.94
Price to Sales (P/S)1.87
P/FCF Ratio14.88
Enterprise Value/Market Cap139.32
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda8.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmology FranchiseA concentrated specialist model in ophthalmology creates durable revenue from prescription therapies and recurring patient demand. Clinical expertise and focused R&D increase barriers to entry, supporting steady product adoption and longer lifecycle earnings versus commodity drug makers.
Debt-free Balance Sheet And Improved ROEZero financial leverage and a strong equity base give the company flexibility to fund R&D, pursue partnerships or M&A, and weather cyclical dips without refinancing risk. Improved ROE indicates capital is generating better returns after the prior loss year, strengthening long-term resilience.
Restored Profitability And Healthy MarginsRe-established positive EBIT and net margins after a loss year supports sustainable cash generation and internal funding for innovation. Margins at current levels allow reinvestment in commercialization while preserving the ability to return capital or fund strategic initiatives over the medium term.
Bears Say
Earnings And Cash-flow VolatilityHistoric swings (including a 2023 loss) and variability in results make multi-quarter forecasting and planning harder. Volatile earnings can limit consistent R&D spending, dividend policy predictability, and investor confidence, increasing execution risk over the next several quarters.
Gross Margin Trending DownA declining gross margin trend signals rising cost pressure or pricing challenges in core products. If sustained, margin erosion would compress operating profits and reduce available cash for R&D or commercialization, weakening long-term profitability and competitive reinvestment capacity.
Limited Disclosure On Product/partner ConcentrationLack of transparent product- and partner-level revenue detail makes it hard to assess concentration risk. Dependence on a few drugs or partners could expose results to regulatory setbacks, patent/launch timing, or partner decisions, raising structural downside risk.
Santen Pharmaceutical Co News
SNPHY FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $9.66 and its highest was $12.20 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.85B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on May 12, 2026. The company reported $0.305 earnings per share for the quarter, beating the consensus estimate of N/A by $0.305.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.128 which represents an annual dividend yield of 2.02%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,290,160 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.305 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.114%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Santen Pharmaceutical Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.01%
12-Months-Change
Fundamentals
Return on Equity
13.15%
Trailing 12-Months
Asset Growth
-2.84%
Trailing 12-Months
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---